IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer
Sun, Yan1; Wang, Jin Wan1; Liu, Yong Yu2; Yu, Qi Tao3; Zhang, Yi Ping4; Li, Kai5; Xu, Li Yan6; Luo, Su Xia7; Qin, Feng Zhan8; Chen, Zheng Tang9; Liu, Wen Chao10; Zhou, Qing Hua11; Chen, Qiang12; Nan, Ke Jun13; Liu, Xiao Qing14; Liu, Wei15; Liang, Hou Jie16; Lu, Hui Shan17; Wang, Xiu Wen18; Wang, Jie Jun19; Song, Shu Ping20; Tu, Yuan Rong21; Zhou, Jing Min22; Li, Wei Lian23; Yao, Chen24; Endostar Phase III NSCLC Study Grp
关键词Advanced And Relapsed Nsclc Angiogenesis Inhibitor Endostar Np Regimen Recombinant Human Endostatin Survival Benefit
刊名THORACIC CANCER
2013-11-01
DOI10.1111/1759-7714.12050
4期:4页:440-448
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Respiratory System
研究领域[WOS]Oncology ; Respiratory System
关键词[WOS]RECOMBINANT HUMAN ENDOSTATIN ; ANGIOGENIC FACTORS ; COLORECTAL-CANCER ; BREAST-CANCER ; TUMOR-GROWTH ; BEVACIZUMAB ; PACLITAXEL ; THERAPY ; CHEMOTHERAPY ; ANGIOSTATIN
英文摘要

Background:Phase II-III trials in patients with untreated and previously treated locally advanced or non-small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum-based chemotherapy (NP regimen) with tolerable adverse effects.

MethodsFour hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles.

Results:Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001).

Conclusion:Long-term follow-up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone.

语种英语
WOS记录号WOS:000326166200015
资助机构Simcere-Medgenn Bioengineering Co.
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58177
专题北京大学第一临床医学院
作者单位1.3rd PLA Med Univ, Xinan Hosp, Chongqing, Peoples R China
2.Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
3.Liaoning Prov Canc Hosp, Shenyang, Peoples R China
4.Zhejiang Prov Canc Hosp, Hengzhou, Peoples R China
5.Tianjin Canc Hosp, Tianjin, Peoples R China
6.Thorac Tumor Hosp, Beijing, Peoples R China
7.Shandong Univ, Qilu Hosp, Jinan 250100, Peoples R China
8.Shandong Prov Canc Hosp, Jinan, Peoples R China
9.Fujian Med Univ, Hosp 1, Fuzhou, Peoples R China
10.Henan Prov Canc Hosp, Zhengzhou, Peoples R China
11.Tianjin Chest Hosp, Tianjin, Peoples R China
12.Tianjin 2nd Hosp, Tianjin, Peoples R China
13.Peking Univ, Hosp 1, Beijing 100871, Peoples R China
14.Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China
15.Xian Commun Univ, Hosp 1, Xian, Peoples R China
16.Hebei Prov Canc Hosp, Shijiazhuang, Peoples R China
17.Anhai Prov Canc Hosp, Hefei, Peoples R China
18.3rd PLA Med Univ, Xianqiao Hosp, Chongqing, Peoples R China
19.4th PLA Med Univ, Xijing Hosp, Xian, Peoples R China
20.Sichun Univ, Huaxi Hosp, Chengdu, Peoples R China
21.Chinese Acad Med Sci, Canc Hosp, Beijing 100021, Peoples R China
22.Guangxi Med Univ, Canc Hosp, Nanning, Guangxi, Peoples R China
23.Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China
24.2nd PLA Med Univ, Changzheng Hosp, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Sun, Yan,Wang, Jin Wan,Liu, Yong Yu,et al. Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer[J]. THORACIC CANCER,2013,4(4):440-448.
APA Sun, Yan.,Wang, Jin Wan.,Liu, Yong Yu.,Yu, Qi Tao.,Zhang, Yi Ping.,...&Endostar Phase III NSCLC Study Grp.(2013).Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer.THORACIC CANCER,4(4),440-448.
MLA Sun, Yan,et al."Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer".THORACIC CANCER 4.4(2013):440-448.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Yan]的文章
[Wang, Jin Wan]的文章
[Liu, Yong Yu]的文章
百度学术
百度学术中相似的文章
[Sun, Yan]的文章
[Wang, Jin Wan]的文章
[Liu, Yong Yu]的文章
必应学术
必应学术中相似的文章
[Sun, Yan]的文章
[Wang, Jin Wan]的文章
[Liu, Yong Yu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。